Ingestible beauty has moved from a side shelf in the Korean supplement aisle into the middle of brand roadmaps. Vitamin A taken by mouth — capsule, powder stick, or jelly — is now one of the formats overseas buyers raise most often when they open a sourcing conversation. The questions they arrive with are rarely about whether it works. They are about which regulatory shelf the product sits on, which factory is allowed to make it, and what the carton can legally say.
That is a different sourcing problem from a serum, and brands that treat it as a simple line extension of their skincare range usually find out late.
The pull is regulatory as much as it is consumer demand
Topical retinoids sit awkwardly in several export markets. Depending on the jurisdiction, a vitamin A derivative in a leave-on product may be capped by concentration, restricted to prescription channels, or subject to mandatory warning text that undercuts the marketing. A brand that wants a vitamin A story in those markets has a choice: reformulate down to a level that barely performs, or move the story somewhere else on the shelf.
Ingestible formats are that somewhere else. They also solve a commercial problem that skincare brands think about constantly — repeat purchase. A capsule taken daily runs out on a predictable schedule, which makes subscription and refill models far easier to build than they are around a 50 ml jar.
None of that is an efficacy argument. It is a distribution and category argument, and it is the reason the format keeps surfacing in briefs from brands whose core range is entirely leave-on skincare.
Two factories, not one
Here is the practical break point. A cosmetics manufacturer operates under cosmetic GMP — ISO 22716 in most export contexts. An ingestible product is food, and it is made in a food plant under food safety management systems, with its own certifications, its own raw material documentation, and its own contamination controls.
These are different buildings with different auditors. A brand that has worked with a cosmetics OEM for three years cannot assume that partner can produce a supplement, and the honest answer from a manufacturer is often a referral rather than a quote.
In Korea, the framework that governs ingestible products making health-related claims is health functional food, administered separately from the Cosmetics Act. Registration, permitted claim language, and the evidence required to support a claim all live in that system. A brand planning both a cream and a capsule is running two regulatory workstreams in parallel, not one with an extra SKU attached.
What the delivery-system story is actually claiming
Almost every brief that mentions oral retinol also mentions liposomal encapsulation. It is worth separating what that technology does from what marketing tends to imply it does.
Encapsulating vitamin A in a lipid layer is a stability measure. Vitamin A degrades on exposure to light, oxygen, and heat, and encapsulation protects the active through processing and shelf life. That is a real formulation benefit and a defensible thing to put on a spec sheet.
It is not, on its own, evidence of a skin outcome. The gap between “protected through manufacture and storage” and “produces visible change in the skin” is where compliance problems start. A manufacturer can tell you what the encapsulation does to stability; substantiating a claim about complexion is a separate exercise with separate documentation, and it belongs to whoever owns the label.
Companion nutrients follow the same logic. Vitamin C, vitamin D, vitamin E, and pantothenic acid appear in most formulations on the market. Each has an established nutritional function. Combining them creates a fuller supplement, not automatically a stronger claim.
The safety conversation you cannot skip
Vitamin A is fat-soluble and accumulates. Retinoids at high systemic doses are established teratogens, which is why prescription oral retinoid therapy carries pregnancy restrictions in every market that permits it. Nutritional supplement doses are a different order of magnitude from therapeutic dosing, but the direction of the risk does not change, and tolerable upper intake levels exist for exactly this reason.
For a brand, this shapes three things. Dosing has to be set against the upper intake level for the target market rather than chosen for a punchier label. Warning and advisory text has to survive translation into every market on the roadmap. And customer service needs an answer ready for the pregnancy question, because it will be asked.
Fat solubility also affects the usage instruction. Taken with a meal containing some fat, absorption is better than on an empty stomach — a small detail that belongs on the pack rather than buried in an FAQ.
What to put in the brief
Most wasted development cycles in this category trace back to a brief that described a marketing concept instead of a product. Before approaching a supplier, settle these:
- Target market first, format second. Permitted claim language and dosing ceilings differ enough between regions that the destination should drive the formulation, not the other way round.
- Format economics. A jelly stick, a softgel, and a powder sachet have different unit costs, different minimum order quantities, and different shelf-life profiles. Pick the one your price point can carry.
- Claim substantiation ownership. Decide early whether the manufacturer supplies supporting documentation or whether that sits with the brand. Ambiguity here delays launches more than formulation work does.
- Shelf-life testing conditions. Ask for the actual storage conditions behind the stated shelf life, especially for products heading to hot or humid markets.
The brands doing well with this category are not the ones with the boldest claims. They are the ones treating an ingestible as a food product with a beauty positioning, rather than a skincare product that happens to be swallowed. The distinction sounds pedantic until an import inspection turns on it.
It also changes how the SKU sits alongside the rest of the range. Used well, an ingestible gives a brand a reason to talk to the same customer on a monthly cycle — something a rinse-off or leave-on product rarely achieves on its own.
“The brands that get an ingestible SKU to market cleanly are the ones who accept early that it is a food product with a beauty positioning, not a skincare product in a capsule. Where we see delays is when a brand briefs an ingestible the way they would brief a serum, then discovers halfway through that the claim language they built the campaign around does not survive the regulatory review in their target market. Buyers sourcing from Korea are genuinely interested in the delivery-technology angle, but the ones who launch on schedule are the ones who settled the destination market and the label copy before they settled the format.” — Hyejin Cho, Digital Marketing Specialist, Marketing and Communication Team at SPSCOS